UPDATE: Goldman On Incyte Notes 'we are constructive on the dermatology franchise (topical ruxolitinib in atopic dermatitis and vitiligo) which represents optionality (not included in model), with Ph3 TRuE-AD data for the former in 1H20'
Benzinga_Newsdesk